Subscribe
Core coverageEXEL

Company profile / EXEL

Exelixis

Clinaptis stanceCautious
ConvictionMedium
Ticker
EXEL
Exchange
NASDAQ
Coverage
Standard profile
Updated
Oct 3, 2026
Oncology / TKI

Commercial-stage oncology company focused on the discovery and development of novel cancer medicines, primarily driven by cabozantinib and the advancing zanzalintinib pipeline.

01 / Clinaptis view

The current read

Exelixis remains a high-quality, cash-generative oncology business, but valuation has moved ahead of the near-term fundamental setup. Cabometyx continues to grow and the balance sheet is strong, yet the franchise faces a meaningful 2030–32 patent-duration question and zanzalintinib still needs to prove that it can become a genuine second franchise rather than an extension of the existing TKI business.

  1. With the shares already reflecting substantial confidence in zanzalintinib, we see an increasingly asymmetric setup around STELLAR-304: a positive result is substantially anticipated, while a miss would challenge the replacement-franchise narrative ahead of eventual Cabometyx erosion.
02 / Consensus gap

Where the market may differ

We think the market is giving zanzalintinib franchise-level credit too early. STELLAR-303 demonstrated an OS benefit in late-line colorectal cancer, but the modest absolute benefit, higher toxicity and combination regimen leave commercial value less established than regulatory success alone would imply.

  1. STELLAR-304 is the more important test of whether zanzalintinib can support a durable second franchise, but at the current valuation much of that validation appears already embedded. The underappreciated risk is therefore not near-term Cabometyx execution, but how much value remains if zanzalintinib merely works rather than materially broadening and extending Exelixis' earnings base.
Coverage state
Standard profile
What the review turns on
Key variable

Pipeline replacement value

Next catalyst

Zanzalintinib · STELLAR-304 Phase 3 topline data · 2H 2026

03 / Pipeline

Key programs

2 assets · 2 programs

AssetIndicationStageNext event
Cabometyx (cabozantinib)
RCC, HCC, NET and other solid tumors
Commercial
Ongoing commercial execution and label-expansion studies
Zanzalintinib (XL092)
Advanced solid tumors
Phase 3
STELLAR-304 topline results in 2H 2026
04 / Connected research

Published on EXEL

View full archive
No published research attached

The profile is live. The research connection is still open.

When a Clinaptis article includes EXEL in its research metadata, it will appear here automatically.

Browse all research